[P68] ポスターセッション 68　臨床試験推進プログラム

[P68-11] Ph2 trial of tucatinib + trastuzumab in previously treated, HER2-altered solid tumors（SGNTUC-019, trial in progress）

^○Yoshiaki Nakamura¹, Tanios S. Bekaii-Saab², Bradley J. Monk³, Alicia F. C. Okines⁴, David M. O'Malley⁵, Paula R. Pohlmann⁶, Martin Reck⁷, Evan Y. Yu⁸, Jorge Ramos⁹, Sherry Tan⁹, Tom Stinchcombe¹⁰ (1.Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, 2.Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA, 3.Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ, USA, 4.The Royal Marsden NHS Foundation Trust, London, United Kingdom, 5.The Ohio State University, The James Comprehensive Cancer Center, Columbus, OH, USA, 6.University of Texas MD Anderson Cancer Center, TX, USA, 7.LungenClinic, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany, 8.Division of Oncology, Department of Medicine, University of Washington, Seattle, WA, USA, 9.Seagen Inc., Bothell, WA, USA, 10.Duke Cancer Institute, Durham, NC, USA)